ETNB Insider Trading

Insider Ownership Percentage: 2.80%
Insider Buying (Last 12 Months): $50,235,693.75
Insider Selling (Last 12 Months): $162,357.42

89bio Insider Trading History Chart

This chart shows the insider buying and selling history at 89bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$91ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

89bio Share Price & Price History

Current Price: $7.40
Price Change: Price Increase of +0.46 (6.63%)
As of 04/28/2025 05:00 PM ET

This chart shows the closing price history over time for ETNB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$7.40Closing price on 04/28/25:

SEC Filings (Institutional Ownership Changes) for 89bio (NASDAQ:ETNB)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ETNB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$2.59Mbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M$0$100MTotal InflowsTotal Outflows
89bio logo
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Read More on 89bio

Today's Range

Now: $7.40
Low: $6.92
High: $7.45

50 Day Range

MA: $7.56
Low: $4.83
High: $11.08

52 Week Range

Now: $7.40
Low: $4.16
High: $11.84

Volume

1,618,523 shs

Average Volume

1,314,190 shs

Market Capitalization

$1.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Who are the company insiders with the largest holdings of 89bio?

89bio's top insider shareholders include:
  1. Ra Capital Management, LP (Director)
  2. Rohan Palekar (CEO)
  3. Quoc Le-Nguyen (Insider)
  4. Charles Mcwherter (Director)
  5. Edward Morrow Atkinson III (Director)
  6. Kathleen Laporte (Director)
Learn More about top insider investors at 89bio.

Who are the major institutional investors of 89bio?

89bio's top institutional shareholders include:
  1. Assenagon Asset Management S.A. — 0.29%
  2. Harbor Capital Advisors Inc. — 0.22%
  3. Rhumbline Advisers — 0.10%
  4. Hennion & Walsh Asset Management Inc. — 0.10%
  5. Teacher Retirement System of Texas — 0.02%
  6. Diversified Trust Co — 0.01%
Learn More about top institutional investors of 89bio stock.

Which institutional investors are buying 89bio stock?

During the previous quarter, ETNB stock was acquired by institutional investors including:
  1. Assenagon Asset Management S.A.
  2. Harbor Capital Advisors Inc.
  3. Hennion & Walsh Asset Management Inc.
  4. Rhumbline Advisers
  5. Diversified Trust Co
  6. GAMMA Investing LLC
  7. Teacher Retirement System of Texas
During the previous year, these company insiders have bought 89bio stock:
  1. Ra Capital Management, LP (Director)
  2. Rohan Palekar (CEO)
  3. Quoc Le-Nguyen (Insider)
Learn More investors buying 89bio stock.